Are GLP-1 Drugs Being Over-Prescribed? A Gut Health Take

In 2020, roughly 900,000 Americans were prescribed a GLP-1 receptor agonist. By 2025, that number had climbed past 15 million. The drugs work — on that point the clinical evidence is unambiguous. Semaglutide and tirzepatide produce weight loss results that lifestyle interventions alone almost never achieve for severely obese patients, and the cardiovascular and kidney disease data is genuinely impressive. But with explosive prescription growth has come a harder question: are we prescribing these drugs to people who will benefit from them, or are we prescribing them to anyone who wants to lose weight? And for people with gut conditions — SIBO, motility disorders, gastroparesis, IBS — is the rush to prescribe happening without adequate consideration of who will be harmed?

The Numbers: A Prescription Boom With Uneven Oversight

GLP-1 receptor agonist prescriptions grew by over 400% between 2021 and 2025, driven by the approval of semaglutide for chronic weight management (Wegovy in 2021), the launch of tirzepatide (Mounjaro for diabetes, Zepbound for obesity), and unprecedented direct-to-consumer marketing. The American Medical Association noted in its 2025 prescribing report that approximately 35% of GLP-1 prescriptions for weight loss were written by primary care physicians who had not obtained any prior GI or metabolic workup — not because they were negligent, but because no standard protocol requiring such workup exists. Prescriptions through telehealth platforms, where physician-patient interaction may be as brief as a 10-minute video call, now account for an estimated 18-22% of all GLP-1 weight loss prescriptions.

The FDA's approved indication for weight management requires a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. In practice, enforcement of these thresholds is largely self-reported. Studies of telehealth GLP-1 prescriptions have found that a meaningful fraction of patients would not meet the clinical criteria if formally measured — obtaining prescriptions based on subjective reports of height, weight, and health status. This is not a fringe phenomenon. It is a structural feature of a healthcare system that has created enormous demand for a medication without creating proportionate infrastructure for appropriately selecting and monitoring patients.

The BMI Threshold Debate: Who Actually Benefits?

The BMI 27-30 threshold for GLP-1 prescribing is not based on evidence that people in this range have the same risk-to-benefit profile as people with BMI above 35. The cardiovascular mortality benefit demonstrated in the SELECT trial enrolled patients with established cardiovascular disease and BMI above 27 — a population with very different health stakes than a healthy 28-year-old who wants to lose 15 pounds before a wedding. Critics of current prescribing patterns argue that the data supporting GLP-1 use becomes progressively thinner as you move down the BMI scale and reduce comorbidity burden.

There is also the question of long-term safety data at low-risk BMI ranges. GLP-1 trials have typically followed patients for 1-2 years. The drugs suppress appetite profoundly — and in patients who are not metabolically obese, this suppression may carry nutritional risks (muscle loss, micronutrient deficiency) that outweigh a modest cosmetic weight loss benefit. Obesity medicine specialists who supported early prescribing expansion are increasingly calling for clearer risk stratification guidelines, particularly distinguishing patients who have metabolic obesity with normal BMI from patients who are simply above their preferred aesthetic weight.

Who Shouldn't Be on a GLP-1 From a Gut Health Perspective

From a gut health standpoint, the patients most at risk from GLP-1 therapy are those with pre-existing motility disorders. Gastroparesis — delayed stomach emptying — is already a complication of long-standing diabetes, and semaglutide further slows gastric emptying. Multiple case reports and a 2024 retrospective cohort study in Clinical Gastroenterology and Hepatology documented new or worsening gastroparesis in diabetic patients on GLP-1 therapy, with some requiring drug discontinuation and hospitalization. Patients with known gastroparesis should generally not be started on GLP-1 drugs without explicit gastroenterological guidance.

Patients with SIBO, intestinal dysmotility, or a history of abdominal surgery leading to altered gut anatomy are similarly at elevated risk. The migrating motor complex (MMC) — the intestinal sweeping mechanism that prevents bacterial accumulation in the small intestine — is suppressed by GLP-1-driven motility changes. For someone whose MMC is already impaired (a common finding in SIBO patients), adding a drug that further suppresses it creates conditions for worsening overgrowth. Yet gut motility assessment is not a standard part of GLP-1 prescribing workup in most clinical settings. Patients with IBS-C (constipation-predominant IBS) also tend to experience worsening constipation on GLP-1 therapy, which can significantly impair quality of life.

The Rush to Prescribe Without GI Monitoring

Even setting aside contraindicated patients, the absence of standardized GI monitoring protocols for people on GLP-1 drugs is a significant gap in current prescribing practice. Nausea, vomiting, diarrhea, and constipation are among the most commonly reported side effects of semaglutide — yet there is no standard recommendation for how frequently a prescribing physician should assess GI symptom burden, when to consider GI referral, or how to adjust dosing based on GI tolerance rather than weight loss outcomes alone. Many patients manage debilitating nausea silently because they believe it is expected, or because they fear their prescription will be discontinued.

A gut health-aware prescribing framework would include a baseline GI symptom assessment before starting therapy, a structured follow-up protocol for GI side effects at weeks 4, 8, and 12 (corresponding to dose escalation points), clear criteria for GI-related dose holds or reductions, and identification of red-flag GI symptoms (severe abdominal pain, inability to tolerate food, signs of obstruction) requiring urgent evaluation. None of this is standard of care in most practices today. Building this infrastructure — particularly in primary care and telehealth settings where most new GLP-1 prescriptions originate — is arguably the most important near-term priority in responsible GLP-1 prescribing.

Questions to Ask Your Prescriber Before Starting a GLP-1 Drug

The answer to whether GLP-1 drugs are being overprescribed is not a simple yes or no. For patients with significant obesity and metabolic disease, the risk-benefit calculus strongly favors treatment — and the tragedy is that many of these patients still cannot access these drugs due to cost and insurance barriers. The overprescribing concern is more specifically about the expansion of prescribing into lower-risk populations without adequate screening, and about the absence of systematic GI monitoring across all prescribing settings. As a patient, you can partially compensate for this gap by asking the right questions before you start.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.